RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 24-Week Data from the Phase 4 ADACTA Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 9
SP 10
OP 11
DO 10.1177/155989771209007
UL http://mdc.sagepub.com/content/12/9/10.abstract
AB Results from the Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis trial [ADACTA; NCT01119859], suggest that tocilizumab monotherapy may be more effective than adalimumab monotherapy reducing the signs and symptoms of rheumatoid arthritis.